Dosage & Administration Drug label Prior authorization Financial assistance Patient education People also ask

Opdivo(nivolumab)

Opdivo 40 MG in 4 ML Injection

NO BOXED WARNING

Dosage & Administration

* Administer by intravenous infusion after dilution based upon recommended infusion rate for each indication. (2)
* Unresectable or metastatic melanoma
* Adult and pediatric patients weighing 40 kg or greater: 240 mg every 2 weeks or 480 mg every 4 weeks. (2.2)
* Pediatric patients weighing less than 40 kg: 3 mg/kg every 2 weeks or 6 mg/kg every 4 weeks. (2.2)
* Adult and pediatric patients weighing 40 kg or greater: 1 mg/kg followed by ipilimumab 3 mg/kg on the same day every 3 weeks for 4 doses, then 240 mg every 2 weeks or 480 mg every 4 weeks. (2.2)
* Pediatric patients weighing less than 40 kg: 1 mg/kg followed by ipilimumab 3 mg/kg on the same day every 3 weeks for 4 doses, then 3 mg/kg every 2 weeks or 6 mg/kg every 4 weeks. (2.2)

* Adjuvant treatment of melanoma
* Adult and pediatric patients weighing 40 kg or greater: 240 mg every 2 weeks or 480 mg every 4 weeks. (2.2)
* Pediatric patients weighing less than 40 kg: 3 mg/kg every 2 weeks or 6 mg/kg every 4 weeks. (2.2)

* Neoadjuvant treatment of resectable (tumors ≥4 cm or node positive) non-small cell lung cancer
* 360 mg with platinum-doublet chemotherapy on the same day every 3 weeks for 3 cycles. (2.2)

* Metastatic non-small cell lung cancer
* 360 mg every 3 weeks with ipilimumab 1 mg/kg every 6 weeks. (2.2)
* 360 mg every 3 weeks with ipilimumab 1 mg/kg every 6 weeks and 2 cycles of platinum-doublet chemotherapy. (2.2)
* 240 mg every 2 weeks or 480 mg every 4 weeks. (2.2)

* Malignant pleural mesothelioma
* 360 mg every 3 weeks with ipilimumab 1 mg/kg every 6 weeks. (2.2)

* Advanced renal cell carcinoma
* 3 mg/kg followed by ipilimumab 1 mg/kg on the same day every 3 weeks for 4 doses, then 240 mg every 2 weeks or 480 mg every 4 weeks. (2.2)
* 240 mg every 2 weeks or 480 mg every 4 weeks administered in combination with cabozantinib 40 mg once daily without food. (2.2)
* 240 mg every 2 weeks or 480 mg every 4 weeks. (2.2)

* Classical Hodgkin lymphoma
* 240 mg every 2 weeks or 480 mg every 4 weeks. (2.2)

* Recurrent or metastatic squamous cell carcinoma of the head and neck
* 240 mg every 2 weeks or 480 mg every 4 weeks. (2.2)

* Adjuvant treatment of urothelial carcinoma
* 240 mg every 2 weeks or 480 mg every 4 weeks. (2.2)

* First-line unresectable or metastatic urothelial carcinoma
* 360 mg every 3 weeks with cisplatin and gemcitabine on the same day for up to 6 cycles, then 240 mg every 2 weeks or 480 mg every 4 weeks. (2.2)

* Previously treated locally advanced or metastatic urothelial carcinoma
* 240 mg every 2 weeks or 480 mg every 4 weeks. (2.2)

* Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer
* Adult and pediatric patients weighing 40 kg or greater: 240 mg every 2 weeks or 480 mg every 4 weeks. (2.2)
* Pediatric patients weighing less than 40 kg: 3 mg/kg every 2 weeks. (2.2)
* Adult and pediatric patients weighing 40 kg or greater: 3 mg/kg followed by ipilimumab 1 mg/kg on the same day every 3 weeks for 4 doses, then 240 mg every 2 weeks or 480 mg every 4 weeks. (2.2)

* Hepatocellular carcinoma
* 1 mg/kg followed by ipilimumab 3 mg/kg on the same day every 3 weeks for 4 doses, then 240 mg every 2 weeks or 480 mg every 4 weeks. (2.2)

* Adjuvant treatment of resected esophageal or gastroesophageal cancer
* 240 mg every 2 weeks or 480 mg every 4 weeks for total treatment duration of 1 year.

* Esophageal squamous cell carcinoma
* 240 mg every 2 weeks or 480 mg every 4 weeks in combination with chemotherapy regimen of fluoropyrimidine- and platinum-containing chemotherapy. (2.2)
* 3 mg/kg every 2 weeks or 360 mg every 3 weeks with ipilimumab 1 mg/kg every 6 weeks. (2.2)
* 240 mg every 2 weeks or 480 mg every 4 weeks. (2.2)

* Gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC, GEJC, or EAC)
* 360 mg every 3 weeks with fluoropyrimidine- and platinum-containing chemotherapy every 3 weeks. (2.2)
* 240 mg every 2 weeks with fluoropyrimidine- and platinum-containing chemotherapy every 2 weeks. (2.2)

* See full Prescribing Information for preparation and administration instructions and dosage modifications for adverse reactions.

drug label

Opdivo Prescribing Information

Contact Medical Science Liaison

Report Adverse Event

prior authorization

Opdivo Prior Authorization Resources

Most recent state uniform prior authorization forms

Verified: Jul 26, 2024Arizona - Uniform Prior Authorization Form

Verified: Jul 26, 2024Colorado - Uniform Prior Authorization Form

Verified: Jul 26, 2024Hawaii - Uniform Prior Authorization Form

Verified: Jul 26, 2024Illinois - Uniform Prior Authorization Form

Verified: Jul 26, 2024Indiana - Uniform Prior Authorization Form

Verified: Jul 26, 2024Louisiana - Uniform Prior Authorization Form

Verified: Jul 26, 2024Minnesota - Uniform Prior Authorization Form

Verified: Jul 26, 2024New Hampshire - Uniform Prior Authorization Form

Verified: Jul 26, 2024New Mexico - Uniform Prior Authorization Form

Verified: Jul 26, 2024Oregon - Uniform Prior Authorization Form

Verified: Jul 26, 2024Texas - Uniform Prior Authorization Form

Verified: Jul 07, 2024Washington - Uniform Prior Authorization Form

Verified: Jul 07, 2024Wisconsin - Uniform Prior Authorization Form

Complete Letter of Medical Necessity

Coverage Authorization Appeals

Commercial Claim Denial Appeal/Redetermination Letter

Medically Unlikely Edit (MUE) Appeal Letter

Benefits investigation

Opdivo Enrollment Form

Opdivo Enrollment Form - Spanish

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information

Financial Assistance

Financial Assistance Programs

Opdivo retails for $331 per dose without insurance or financial assistance.Depending on your patient's insurance situation and other eligibility criteria, they may be able to get Opdivo for significantly less. Review the program information below to determine what program can offer your patient the most benefits.

Copay Card Program$0 Copay

Available for

commercial

Program Details

Program Expires Calendar Year

Forms

Opdivo Enrollment Form

Opdivo Enrollment Form - Spanish

Enroll in Patient Savings Program

patient education

Opdivo Patient Education

To share resource; ask patient to:

1.Pull out phone

2.Open camera

3.Scan QR code with camera

4.Tap link